A False Claims Act suit was unsealed alleging that Johnson & Johnson fraudulently obtained a patent to block generic competition for prostate cancer drug Zytiga (abiraterone acetate), a drug that costs roughly $9,000 per month and generates about $2.4 billion in annual revenue for New Brunswick, N.J.-based J&J, according to law firm Herrera Purdy LLP.